Clinical trials: in Latvia
Primary Prevention, Tachycardia, Ventricular
Survival of Patients With Primary Prophylactic ICD Indication
The MADIT-II trial has shown that patients with severely reduced left ventricular ejection fraction (LVEF) post myocardial infarction benefit from the implantable cardioverter-defibrillator (ICD).
- Conditions
- Primary Prevention, Tachycardia, Ventricular, Sudden Cardiac Death
- Trial name
- SPIRIT-ICD (NCT00619593)
- Testing
- Intensified diagnostic and treatment measures following 1st appropriate ICD therapy, Standard follow-up
- Where
- 37 sites in Austria, Czechia and 9 more
- Volunteers
- 504 people
- Sponsor
- Biotronik SE & Co. KG
Prostate Cancer
Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning
The primary objective of the PHSTT-01 trial is to determine if prostate HistoScanning (HS) analysis can be used to improve the detection of clinically significant prostate cancer (PCa), and potentially reduce the burden and…
- Trial name
- PHSTT-01 (NCT01950871)
- Testing
- Prostate HistoScanning
- Where
- 34 sites in Austria, Belgium and 16 more
- Volunteers
- 80 people
- Sponsor
- Advanced Medical Diagnostics s.a.
Ventricular Fibrillation, Ventricular Tachycardia
Influence of Home Monitoring on the Clinical Status of Heart Failure Patients With an Impaired Left Ventricular Function
Re-hospitalizations or deaths by worsening heart failure are often preceded by distinct trends of clinical parameters such as atrial or ventricular arrhythmia, activity, heart rate variability, or ventricular ectopy.
- Conditions
- Ventricular Fibrillation, Ventricular Tachycardia, Congestive Heart Failure
- Trial name
- IN-TIME (NCT00538356)
- Testing
- ICD or CRT-D with Home Monitoring feature deactivated, ICD or CRT-D with Home Monitoring feature activated
- Where
- 39 sites in Australia, Austria and 5 more
- Volunteers
- 720 people
- Sponsor
- Biotronik SE & Co. KG
Plaque Psoriasis
Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The primary objectives of the study are: To evaluate the safety and tolerability of three dose levels of MT-1303 in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01987843
- Testing
- MT-1303-Low, MT-1303-Middle, MT-1303-High
- Where
- 52 sites in Bulgaria, Estonia and 6 more
- Volunteers
- 142 people
- Sponsor
- Tanabe Pharma Corporation
Ocular Hypertension, Primary Open Angle Glaucoma
A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension
The objective of this Phase 1 study is to evaluate the VISION5 Product's safety and efficacy.
- Trial name
- NCT01943721
- Testing
- VISION5 Product
- Where
- Latvia
- Volunteers
- 14 people
- Sponsor
- ForSight Vision5, Inc.
Macular Degeneration
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
- Trial name
- VIEW 2 (NCT00637377)
- Testing
- Ranibizumab, Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- Where
- 189 sites in Argentina, Australia and 24 more
- Volunteers
- 1,240 people
- Sponsor
- Bayer
Overactive Bladder Syndrome (OABS)
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
SMP-986 is a compound being developed for the treatment of overactive bladder syndrome (OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of 20mg, 40mg, 80mg or 120mg provides greater symptom…
- Trial name
- NCT00409539
- Testing
- SMP-986
- Where
- 69 sites in United States, Estonia and 7 more
- Volunteers
- 550 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Bronchitis
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis
A study to assess the safety and efficacy of moxifloxacin compared to that of amoxicillin-clavulanic acid for the treatment of subjects with acute exacerbation of chronic bronchitis.
- Trial name
- NCT00656747
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Amoxicillin clavulanic acid
- Where
- 220 sites in Andorra, Argentina and 29 more
- Volunteers
- 1,372 people
- Sponsor
- Bayer
Major Depressive Disorder
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
The primary purpose of this study is to compare the long-term efficacy and safety of desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive Disorder, using a randomized withdrawal design.
- Trial name
- NCT00887224
- Testing
- Desvenlafaxine succinate sustained release 50 mg, Desvenlafaxine succinate sustained release 25 mg
- Where
- 90 sites in United States, Canada and 12 more
- Volunteers
- 874 people
- Sponsor
- Pfizer
Infection
Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem
A study to compare the safety and efficacy of moxifloxacin to ertapenem in patients with intra-abdominal infections.
- Trial name
- NCT00492726
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Ertapenem intravenous
- Where
- 52 sites in Argentina, Belgium and 12 more
- Volunteers
- 804 people
- Sponsor
- Bayer
Abscess, Wound Infection
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
Patients, who are considered suitable by their physicians to take part in this research, will have a physical examination (including an Electrocardiogram (ECG)), blood and urine samples taken, as well as a sample of the…
- Conditions
- Abscess, Wound Infection, Diabetic Foot, Ulcer
- Trial name
- NCT00402727
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
- Where
- 123 sites in Austria, Belgium and 18 more
- Volunteers
- 813 people
- Sponsor
- Bayer
Retinal Vein Occlusion
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
To determine the efficacy of vascular endothelial growth factor (VEGF) Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion
- Trial name
- GALILEO (NCT01012973)
- Testing
- Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- Where
- 73 sites in Australia, Austria and 8 more
- Volunteers
- 177 people
- Sponsor
- Bayer
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo, as add-on controller therapy…
- Trial name
- NCT01277523
- Testing
- tiotropium high dose, tiotropium low dose
- Where
- 69 sites in United States, Argentina and 12 more
- Volunteers
- 392 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30 weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual monotherapies of pioglitazone (15 mg, 30…
- Trial name
- NCT01183013
- Testing
- Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg
- Where
- 132 sites in United States, Estonia and 4 more
- Volunteers
- 936 people
- Sponsor
- Boehringer Ingelheim
Atherosclerosis, Coronary Artery Disease
The OMEGA Clinical Trial
The purpose of this study is to evaluate the safety and effectiveness of the OMEGA Coronary Stent System for the treatment of subjects with a de novo atherosclerotic coronary artery lesion.
- Trial name
- NCT01419171
- Testing
- OMEGA™ Monorail Coronary Stent System
- Where
- 37 sites in United States, Belgium and 5 more
- Volunteers
- 328 people
- Sponsor
- Boston Scientific Corporation
Relapsing Multiple Sclerosis
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
The primary objective of this study is to determine the efficacy of peginterferon beta-1a in reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis (RMS) at 1 year.
- Trial name
- ADVANCE (NCT00906399)
- Testing
- BIIB017 (peginterferon beta-1a)
- Where
- 178 sites in United States, Belgium and 24 more
- Volunteers
- 1,516 people
- Sponsor
- Biogen
Dermatitis, Atopic, Eczema, Atopic
Long-term Safety of Protopic in Atopic Eczema
Patients who have participated in previous studies with Tacrolimus ointment for atopic eczema are entitled to enter this four-year follow study to investigate the safety of treatment with Tacrolimus ointment 0.1%
- Trial name
- NCT00560378
- Testing
- Tacrolimus ointment 0.1%
- Where
- 41 sites in Belgium, Denmark and 10 more
- Volunteers
- 789 people
- Sponsor
- Astellas Pharma Inc
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma
The aim of the study is to evaluate efficacy and safety of a 48-week treatment with two doses of tiotropium bromide compared to placebo in adolescent patients with moderate persistent asthma.
- Trial name
- NCT01257230
- Testing
- tiotropium Respimat low dose, tiotropium Respimat high dose
- Where
- 66 sites in United States, Chile and 10 more
- Volunteers
- 398 people
- Sponsor
- Boehringer Ingelheim
Relapsing Remitting Multiple Sclerosis
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
This was a multicenter, randomized, open-label, parallel-group, active-controlled study. Prior to randomization, participants were to have been treated with glatiramer acetate or interferon β-1a (44 μg).
- Trial name
- SURPASS (NCT01058005)
- Testing
- BG00002 (natalizumab), interferon beta-1a, glatiramer acetate
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 84 people
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.